CLINICAL TRIALS PROFILE FOR UBROGEPANT
✉ Email this page to a colleague
All Clinical Trials for UBROGEPANT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02828020 ↗ | Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine | Completed | Allergan | Phase 3 | 2016-07-22 | This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo for the acute treatment of a single migraine attack. |
| NCT02867709 ↗ | Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine | Completed | Allergan | Phase 3 | 2016-08-26 | This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack. |
| NCT02873221 ↗ | An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine | Completed | Allergan | Phase 3 | 2016-09-13 | This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year. |
| NCT04179474 ↗ | Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine | Completed | Allergan | Phase 1 | 2019-09-26 | This study will evaluate the potential for a pharmacokinetic (PK) interaction and provide safety and tolerability information when ubrogepant and erenumab or ubrogepant and galcanezumab are co-administered. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for UBROGEPANT
Condition Name
Clinical Trial Locations for UBROGEPANT
Trials by Country
Clinical Trial Progress for UBROGEPANT
Clinical Trial Phase
Clinical Trial Sponsors for UBROGEPANT
Sponsor Name
